PSILORIS

Educational resource only. Not medical advice. Psilocybin remains illegal or restricted in many jurisdictions.

Full safety notice
← All conditions
Promising evidence

Anxiety Disorders & Cancer-Related Anxiety

High-quality trials in cancer-related anxiety and a dedicated Phase 2 GAD program show clinically meaningful anxiolytic signals. Meta-analyses support post-acute anxiety reductions, while primary panic disorder remains understudied and is tracked separately.

Last reviewed: 2026-07-24

Evidence narrative

Evidence section. Peer-reviewed findings and evidence-graded interpretation only.

Why anxiety appears here

Anxiety is one of the most active psilocybin research domains. The evidence base now includes cancer-related existential anxiety RCTs, a dedicated Phase 2 GAD trial with positive topline results, quantitative meta-analysis, and multiple ongoing protocols spanning high-dose assisted therapy and microdosing designs.

Evidence snapshot

  • Cancer-related anxiety: Griffiths et al. (2016) and Ross et al. (2016) showed large, sustained reductions in anxiety and depression after supervised high-dose sessions; Grob et al. (2011) provided earlier feasibility and trait-anxiety signal.
  • Primary GAD: PsiGAD1 topline results (Incannex, 2024) reported a 12.8-point HAM-A reduction versus 3.6 with psychotherapy plus placebo, with substantially higher response and remission rates.
  • Syntheses: Goldberg et al. (2020) and Castro Santos & Gama Marques support post-acute anxiolytic effects across classical psychedelic studies, while noting bias and heterogeneity limits.
  • Pipeline: PSiGAD2, RE104, oral-solution, and at-home microdosing protocols are expanding dose, setting, and formulation questions.

Candidate vs promising nuance

PSILORIS keeps the broad anxiety category promising because cancer-anxiety RCTs and the first dedicated GAD Phase 2 signal are stronger than for many other indications. Primary panic disorder is treated separately and remains a research gap rather than a proven indication.

Safety notes especially relevant to anxiety

Intense acute anxiety can occur during sessions. People with unstable panic, unmanaged trauma, or inadequate support systems need careful risk assessment. Abrupt cessation of prescribed anxiolytics or antidepressants to chase a psychedelic session can be dangerous and must only happen under medical supervision.

Citations

[2] systematic review · 2021

Efficacy and Safety of Psychedelics in Treating Anxiety Disorders

Castro Santos H, Gama Marques J — Primary Care Companion for CNS Disorders / related clinical literature

Reviewed nine psychedelic-assisted clinical trials across anxiety indications and reported encouraging symptom reductions with an acceptable reported safety profile.

[10] review · 2025

Clinical trial of at-home micro-dose psilocybin now underway

Soares C et al. / Queen's University & KHSC Research Institute — Queen's Faculty of Health Sciences announcement

Health Canada-approved Phase 2a program testing daily at-home non-hallucinogenic/micro-dose psilocybin for GAD (target up to ~60 participants).

[12] review · 2008

Human hallucinogen research: guidelines for safety

Johnson MW, Richards WA, Griffiths RR — Journal of Psychopharmacology

Foundational safety framework for human psychedelic research covering screening, set and setting, session monitoring, and aftercare.

DOI: 10.1177/0269881108093587

[13] review · 2018

Psychiatry & the psychedelic drugs. Past, present & future

Rucker JJH, Iliff J, Nutt DJ — Neuropharmacology

Reviews historical and contemporary psychiatric use of psychedelics, including safety considerations, study design challenges, and research priorities.

DOI: 10.1016/j.neuropharm.2017.12.040

Anecdotal reports

Anecdote section. Not clinical evidence. Included for context and research-question generation only.

Supervised weight-based session with clinician-confirmed anxiety remission

Setting: Researcher-supervised session followed by medical doctor review · Published 2026-07-24

Anecdote label

This is a first-person anecdotal report, not a clinical trial outcome. It is included to illustrate why people seek research on anxiety and panic, and must not be read as proof of efficacy.

Summary of the reported experience

After years on conventional psychiatric medication for anxiety and panic symptoms, the reporter described a single supervised, weight-based psilocybin session. Symbolic imagery during the session was later associated — by the reporter — with a sudden and lasting drop in background anxiety and panic. A subsequent medical review reportedly confirmed that antidepressants and benzodiazepines were no longer required, with only limited sleep-related medication continued.

Why PSILORIS includes this carefully

  • It matches themes studied in anxiety and depression research: rapid shifts in rigid fear patterns and meaning-making.
  • It also highlights real-world complexity: medication changes, medical follow-up, and recurrence monitoring.

What this does not establish

  • Population-level response rates
  • Safe medication discontinuation practices
  • Appropriateness of unsupervised use
  • Legal availability in any specific country

Abruptly stopping prescribed psychiatric medicines can be dangerous. Any medication change belongs under clinician guidance.